Mismatch repair pathway is frequently dysregulated across cancer types, commonly represented by loss of MLH1 or MSH2 gene expression. Here the authors model MLH1 missense mutations from patients to study how cytoplasmic localization of MLH1, promotes resistance to endocrine therapy but predicts response to cell cycle inhibitors in breast cancer.
- Aloran Mazumder
- Jerry Dewitt
- Svasti Haricharan